Clinical trials: Pulmonary Hypertension, Primary
Pulmonary Arterial Hypertension
A Study of RVT-1201 in Patients With Pulmonary Arterial Hypertension (ELEVATE 1)
This is an exploratory Phase 2a, randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic effects of RVT-1201 in patients with…
- Trial name
- NCT03924154
- Testing
- RVT-1201
- Where
- 23 sites in United States, Canada
- Volunteers
- 3 people
- Sponsor
- Altavant Sciences GmbH
Pulmonary Arterial Hypertension
Bioequivalence Study of Riociguat 2.5 mg Film Coated Tablets and Adempas (Riociguat) 2.5 mg Film Coated Tablets
Single dose oral bioequivalence study of Riociguat 2.5 mg film coated tablets and 'Adempas' (Riociguat) 2.5 mg Filmtabletten (film coated tablets) in healthy adult male subjects under fasting conditions.
- Trial name
- NCT06180096
- Testing
- Riociguat film coated tablets, Adempas Filmtabletten
- Where
- India
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Humanis Saglık Anonim Sirketi
Pulmonary Arterial Hypertension
A Long Term Extension Study Evaluating Safety Of Sildenafil Citrate When Used To Treat Pulmonary Arterial Hypertension (PAH) In Children
Active treatment, dose-blinded extension study evaluating the safety and long term efficacy of sildenafil citrate in children with PAH.
- Trial name
- NCT00159874
- Testing
- Sildenafil citrate
- Where
- 39 sites in United States, Brazil and 13 more
- Volunteers
- 234 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Pulmonary Arterial Hypertension
Effect of Selexipag on Daily Life Physical Activity of Patients With Pulmonary Arterial Hypertension.
The primary objective of this study is to evaluate the effect of selexipag on the physical activity of patients with pulmonary arterial hypertension (PAH) in their daily life, by using a wearable wrist device (actigraph).
- Trial name
- TRACE (NCT03078907)
- Testing
- Selexipag
- Where
- 39 sites in United States, Austria and 8 more
- Volunteers
- 108 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension
Pilot Study of the Safety and Efficacy of Carvedilol in Pulmonary Arterial Hypertension
The purpose of this study is to determine whether carvedilol treatment of patients with pulmonary arterial hypertension and associated right heart failure is safe and results in an improved function of the right heart.
- Trial name
- NCT00964678
- Testing
- Carvedilol
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Virginia Commonwealth University
Pulmonary Arterial Hypertension, Right Heart Failure
Repurposing a Histamine Antagonist to Benefit Patients With Pulmonary Hypertension
This is a Phase 2, single-center, randomized placebo controlled trial of famotidine (an H2 receptor antagonist) in adults with pulmonary arterial hypertension.
- Trial name
- REHAB-PH (NCT03554291)
- Testing
- Famotidine 20 MG
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- University of Washington
Hypertension;Pulmonary;Primary
Observational Study of Actigraphy in Pediatric Pulmonary Arterial Hypertension
This study plans to learn more about activity levels in children with pulmonary hypertension. Pulmonary hypertension is a condition where the pressure in the lungs is higher than normal. This can affect the person's heart.
- Trial name
- NCT04745000
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Hypertension, Pulmonary Artery, Ventricular Dysfunction, Left
Characterization of LV Strain Patterns in Mildly Elevated PCWP and PAH.
The purpose of this study is to determine if patients with pulmonary hypertension and mildly elevated heart pressure known as PCWP will exhibit different patterns on echocardiography and that these patterns will predict treatment…
- Trial name
- LV strain (NCT01800292)
- Testing
- sildenafil
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Arizona
Hypertension, Pulmonary
Phase IV Study of Chronic Infusional Epoprostenol for Severe Primary Pulmonary Hypertension
OBJECTIVES: I. Provide epoprostenol (Flolan, prostaglandin I2) by chronic infusion to patients with severe primary pulmonary hypertension for whom no alternative therapy is available. II.
- Trial name
- NCT00004754
- Testing
- epoprostenol
- Sponsor
- National Center for Research Resources (NCRR)
Pulmonary Arterial Hypertension
Effect of Morphine on Dyspnea and 6-Minute Walk Distance in Pulmonary Arterial Hypertension
Despite advances in treatment and corresponding improvements in survival, patients with pulmonary arterial hypertension (PAH) remain highly symptomatic.
- Trial name
- NCT03401476
- Testing
- Morphine Sulfate
- Where
- Canada
- Volunteers
- 15 people
- Sponsor
- John Granton
Pulmonary Arterial Hypertension
Goal Oriented Strategy to Preserve Ejection Fraction Trial
In this prospective long term feasibility study we examine whether a goal oriented therapeutic strategy that is able to preserve right ventricular function will result in improved clinical outcome in patients with pulmonary…
- Trial name
- GOSPEL (NCT03236818)
- Testing
- ERA and PDE-5I (Sildenafil, Tadalafil, Bosentan, Macitentan)
- Where
- Netherlands
- Volunteers
- 30 people
- Sponsor
- Amsterdam UMC, location VUmc
Amyotrophic Lateral Sclerosis (ALS), Angina, Stable
Quest to Analyze One Thousand Humans Meditating
This study will be focused on assessing the molecular, physiological, and emotional correlates of an intensive meditation experience in the context of a retreat setting in a large 2000 plus-person cohort comprised of healthy and…
- Conditions
- Amyotrophic Lateral Sclerosis (ALS), Angina, Stable, Anxiety, Asthma
- Trial name
- QUANTUM (NCT06583395)
- Testing
- Advanced multi-component meditation practice
- Where
- United States
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Tobias Moeller-Bertram
Coronary Artery Disease, Heart Failure
Stress Echo 2020 - The International Stress Echo Study
Background: Stress echocardiography (SE) has an established role in evidence-based guidelines, but recently the breadth and variety of applications has extended well beyond coronary artery disease (CAD).
- Conditions
- Coronary Artery Disease, Heart Failure, Hypertrophic Cardiomyopathy, Aortic Valve Disease
- Trial name
- SE2020 (NCT03049995)
- Testing
- Left ventricular contractile reserve SE, B-lines SE, Left ventricular outflow tract gradient SE
- Where
- Italy
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Fatebenefratelli Hospital
Congenital Heart Disease, Pulmonary Arterial Hypertension
Efficacy of Triple-Combination Therapy in Severe PAH-CHD
Congenital heart disease (CHD) is a leading cause of pulmonary arterial hypertension (PAH) worldwide. Treatment for PAH associated with CHD (PAH-CHD) depends on the defect's type, size, and hemodynamic impact.
- Trial name
- NCT06196801
- Testing
- Triple-combination therapy
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Guangdong Provincial People's Hospital
Acne Vulgaris, Allergic Rhinitis
MedlinePlus Health Prescriptions: Developing a Pragmatic Approach for Clinic Use
The specific aim of this proposed pilot study is to compare two standardized processes (paper and electronic) to deliver a customized MedlinePlus health information prescription.
- Conditions
- Acne Vulgaris, Allergic Rhinitis, Anxiety, Asthma
- Trial name
- NCT01050465
- Testing
- health information prescription
- Volunteers
- 907 people, healthy volunteers welcome
- Sponsor
- University of Missouri-Columbia
Idiopathic Pulmonary Arterial Hypertension
Safety and Feasibility of Autologous Endothelial Progenitor Cells Transplantation in Patients With Idiopathic Pulmonary Arterial Hypertension
Recent researches indicate that impairment of vascular and endothelial homeostasis plays a major role in the initiation and development of IPAH.We have recently reported the safety and feasibility data for autologous endothelial…
- Trial name
- NCT00641836
- Testing
- Transplantation of autologous endothelial progenitor cells
- Where
- China
- Volunteers
- 98 people
- Sponsor
- Zhejiang University
Systemic Sclerosis
Hemodynamic Changes in Connective Tissue Disease
The study serves the identification of early forms of pulmonary arterial hypertension (PAH) in connective tissue disease and the hemodynamic follow-up of the investigated patients.
- Trial name
- NCT01468792
- Where
- Austria
- Volunteers
- 85 people
- Sponsor
- Medical University of Graz
Pulmonary Arterial Hypertension
Safety, Tolerability, Pharmacokinetics and Efficacy of Two Different Rates of Subcutanous Remodulin® Dose Titration in Pulmonary Arterial Hypertension
This is an open-label, multicenter, parallel, randomized (1:1 Slow Dose Titration Group; Rapid Dose Titration Group), two-group study to evaluate the safety, tolerability, pharmacokinetics and efficacy of slow and rapid dose…
- Trial name
- NCT02893995
- Testing
- Slow Dose Titration Group of Subcutaneous Treprostinil, Rapid Dose Titration Group of Subcutaneous Treprostinil
- Where
- 10 sites in China
- Sponsor
- United Therapeutics
Pulmonary Arterial Hypertension
Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)
The primary objectives of the study are to evaluate the safety and tolerability, and pharmacokinetics (PK) of sotatercept over 24 weeks of treatment in children ≥1 to <18 years of age with PAH World Health Organization (WHO)…
- Trial name
- MOONBEAM (NCT05587712)
- Testing
- Sotatercept
- Where
- 35 sites in United States, Australia and 10 more
- Volunteers
- 42 people
- Sponsor
- Merck Sharp & Dohme LLC
Hypertension,Pulmonary
The Screening and Analysis of Plasma Biomarkers in Irreversible PAH-CHD
The purpose of this study is to analyse the sensitivity and specificity of circulating endothelial cells to predict irreversible pulmonary arterial hypertension associated with congenital heart disease.
- Trial name
- NCT02267200
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine